1. Visualization of fidaxomicin association with the exosporium layer of Clostridioides difficile spores.
- Author
-
Bassères E, Endres BT, Montes-Bravo N, Pérez-Soto N, Rashid T, Lancaster C, Begum K, Alam MJ, Paredes-Sabja D, and Garey KW
- Subjects
- Clostridioides difficile cytology, Genetic Variation, Mutation, Ribotyping, Anti-Bacterial Agents therapeutic use, Cell Wall drug effects, Clostridioides difficile drug effects, Clostridioides difficile genetics, Clostridium Infections drug therapy, Fidaxomicin therapeutic use, Spores, Bacterial cytology, Spores, Bacterial drug effects
- Abstract
Background: Fidaxomicin has novel pharmacologic effects on C. difficile spore formation including outgrowth inhibition and persistent spore attachment. However, the mechanism of fidaxomicin attachment on spores has not undergone rigorous microscopic studies., Materials & Methods: Fidaxomicin attachment to C. difficile spores of three distinct ribotypes and C. difficile mutant spores with inactivation of exosporium or spore-coat protein-coding genes were visualized using confocal microscopy with a fidaxomicin-bodipy compound (green fluorescence). The pharmacologic effect of the fidaxomicin-bodipy compound was determined. Confocal microscopy experiments included direct effect on C. difficile wild-type and mutant spores, effect of exosporium removal, and direct attachment to a comparator spore forming organism, Bacillus subtilis., Results: The fidaxomicin-bodipy compound MIC was 1 mg/L compared to 0.06 mg/L for unlabeled fidaxomicin, a 16-fold increase. Using confocal microscopy, the intracellular localization of fidaxomicin into vegetative C. difficile cells was observed consistent with its RNA polymerase mechanism of action and inhibited spore outgrowth. The fidaxomicin-bodipy compound was visualized outside of the core of C. difficile spores with no co-localization with the membrane staining dye FM4-64. Exosporium removal reduced fidaxomicin-bodipy association with C. difficile spores. Reduced fidaxomicin-bodipy was observed in C. difficile mutant spores for the spore surface proteins CdeC and CotE., Conclusion: This study visualized a direct attachment of fidaxomicin to C. difficile spores that was diminished with mutants of specific exosporium and spore coat proteins. These data provide advanced insight regarding the anti-spore properties of fidaxomicin., Competing Interests: Declaration of competing interest KW Garey: Research support from Merck & Co. All other authors: None to declare., (Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF